{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:52Z","timestamp":1792785052091,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing Natural Science Foundation","award":["no. CSTB2022NSCQ-MSX0189"],"award-info":[{"award-number":["no. CSTB2022NSCQ-MSX0189"]}]},{"name":"National Natural Science Foundation of China","award":["nos. 82372758 and 82573508"],"award-info":[{"award-number":["nos. 82372758 and 82573508"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Key Project of Chongqing Natural Science Foundation","award":["CSTB2024NSCQ-KJFZZDX0008"],"award-info":[{"award-number":["CSTB2024NSCQ-KJFZZDX0008"]}]},{"name":"Key Project of Chongqing Natural Science Foundation","award":["no. CSTB2024NSCQ-KJFZZDX0007"],"award-info":[{"award-number":["no. CSTB2024NSCQ-KJFZZDX0007"]}]},{"name":"Chongqing Distinguished Young Scholars Program","award":["no. CSTB2025NSCQ-JQX0003"],"award-info":[{"award-number":["no. CSTB2025NSCQ-JQX0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60910-2","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:04:37Z","timestamp":1783695877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Memory B cells in mature follicle-like tertiary lymphoid structures predict BCG response in non-muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Haitao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-ang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiubo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangkun","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yapeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luofu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-195X","authenticated-orcid":false,"given":"Weihua","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"60910_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA. Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA. Cancer J. Clin."},{"key":"60910_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75\u201394 (2022).","journal-title":"Eur. Urol."},{"key":"60910_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"P-U Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m, P.-U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer. Eur. Urol. 56, 247\u2013256 (2009).","journal-title":"Eur. Urol."},{"key":"60910_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"R J\u00e4rvinen","year":"2009","unstructured":"J\u00e4rvinen, R., Kaasinen, E., Sankila, A. & Rintala, E. Long-term efficacy of maintenance Bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: A subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur. Urol. 56, 260\u2013265 (2009).","journal-title":"Eur. Urol."},{"key":"60910_CR5","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore, N. D. et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: The randomized phase 3 CREST trial. Nat. Med. 31, 2806\u20132814 (2025).","journal-title":"Nat. Med."},{"key":"60910_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.12.022","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti, P. et al. Efficacy and safety of checkpoint inhibitors combined with bacillus calmette-gu\u00e9rin (BCG) in BCG-na\u00efve high-risk non\u2013muscle-invasive bladder cancer: Synthesis of evidence from the ALBAN, CREST, and POTOMAC trials. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.022 (2025).","journal-title":"Eur. Urol."},{"key":"60910_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","volume":"74","author":"Z Klaassen","year":"2018","unstructured":"Klaassen, Z. et al. Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: New insights and updated recommendations. Eur. Urol. 74, 597\u2013608 (2018).","journal-title":"Eur. Urol."},{"key":"60910_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","volume":"73","author":"AM Kamat","year":"2018","unstructured":"Kamat, A. M. et al. Predicting response to intravesical bacillus calmette-gu\u00e9rin immunotherapy: Are we there yet? A systematic review. Eur. Urol. 73, 738\u2013748 (2018).","journal-title":"Eur. Urol."},{"key":"60910_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005518","volume":"11","author":"JH van Puffelen","year":"2023","unstructured":"van Puffelen, J. H. et al. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections. J. Immunother. Cancer 11, e005518 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"60910_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","volume":"41","author":"CM Laumont","year":"2023","unstructured":"Laumont, C. M. & Nelson, B. H. B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 41, 466\u2013489 (2023).","journal-title":"Cancer Cell"},{"key":"60910_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","volume":"40","author":"SM Downs-Canner","year":"2022","unstructured":"Downs-Canner, S. M., Meier, J., Vincent, B. G. & Serody, J. S. B cell function in the tumor microenvironment. Annu. Rev. Immunol. 40, 169\u2013193 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"60910_CR12","doi-asserted-by":"publisher","first-page":"djw144","DOI":"10.1093\/jnci\/djw144","volume":"108","author":"MD Iglesia","year":"2016","unstructured":"Iglesia, M. D. et al. Genomic analysis of immune cell infiltrates across 11 tumor types. J. Natl. Cancer Inst. 108, djw144 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"60910_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.humpath.2016.03.022","volume":"54","author":"K Garg","year":"2016","unstructured":"Garg, K. et al. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum. Pathol. 54, 157\u2013164 (2016).","journal-title":"Hum. Pathol."},{"key":"60910_CR14","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1158\/2326-6066.CIR-23-1114","volume":"12","author":"P Yolmo","year":"2024","unstructured":"Yolmo, P. et al. Atypical B cells promote cancer progression and poor response to bacillus calmette-gu\u00e9rin in non\u2013muscle invasive bladder cancer. Cancer Immunol. Res. 12, 1320\u20131339 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"60910_CR15","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.21037\/tau-21-158","volume":"10","author":"JA Sanders","year":"2021","unstructured":"Sanders, J. A. et al. Genomic analysis of response to bacillus calmette-gu\u00e9rin (BCG) treatment in high-grade stage 1 bladder cancer patients. Transl. Androl. Urol. 10, 2998\u20133009 (2021).","journal-title":"Transl. Androl. Urol."},{"key":"60910_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441\u2013457 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"60910_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"J-L Teillaud","year":"2024","unstructured":"Teillaud, J.-L., Houel, A., Panouillot, M., Riffard, C. & Dieu-Nosjean, M.-C. Tertiary lymphoid structures in anticancer immunity. Nat. Rev. Cancer 24, 629\u2013646 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"60910_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41590-021-01078-x","volume":"23","author":"NM Weisel","year":"2022","unstructured":"Weisel, N. M. et al. Surface phenotypes of naive and memory B cells in mouse and human tissues. Nat. Immunol. 23, 135\u2013145 (2022).","journal-title":"Nat. Immunol."},{"key":"60910_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41584-024-01179-5","volume":"20","author":"T D\u00f6rner","year":"2024","unstructured":"D\u00f6rner, T. & Lipsky, P. E. The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 20, 770\u2013782 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"60910_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"60910_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71340-z","volume":"10","author":"S-M Son","year":"2020","unstructured":"Son, S.-M. et al. Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients. Sci. Rep. 10, 14293 (2020).","journal-title":"Sci. Rep."},{"key":"60910_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"60910_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-03952-1","volume":"74","author":"S Xu","year":"2025","unstructured":"Xu, S. et al. Distinct maturity and spatial distribution of tertiary lymphoid structures in head and neck squamous cell carcinoma: Implications for tumor immunity and clinical outcomes. Cancer Immunol. Immunother. 74, 107 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"60910_CR24","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.21037\/tlcr-2025-477","volume":"14","author":"Y-M Liu","year":"2025","unstructured":"Liu, Y.-M. et al. Density and maturity ratio of tertiary lymphoid structures in stage II\u2013III non-small cell lung cancer predict postoperative recurrence risk. Transl. Lung Cancer Res. 14, 3349\u20133362 (2025).","journal-title":"Transl. Lung Cancer Res."},{"key":"60910_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527-541.e5 (2022).","journal-title":"Immunity"},{"key":"60910_CR26","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman, W. H. et al. Tertiary lymphoid structures and B cells: An intratumoral immunity cycle. Immunity 56, 2254\u20132269 (2023).","journal-title":"Immunity"},{"key":"60910_CR27","doi-asserted-by":"publisher","first-page":"107635","DOI":"10.1016\/j.isci.2023.107635","volume":"26","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Computerized tertiary lymphoid structures density on H&E-images is a prognostic biomarker in resectable lung adenocarcinoma. iScience 26, 107635 (2023).","journal-title":"iScience"},{"key":"60910_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.877689","volume":"13","author":"H Zhao","year":"2022","unstructured":"Zhao, H., Wang, H., Zhao, Y., Sun, Q. & Ren, X. Tumor-resident T cells, associated with tertiary lymphoid structure maturity, improve survival in patients with stage III lung adenocarcinoma. Front. Immunol. 13, 877689 (2022).","journal-title":"Front. Immunol."},{"key":"60910_CR29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-1130","author":"M Lauss","year":"2022","unstructured":"Lauss, M., Donia, M. & Svane, I. M. B cells and tertiary lymphoid structures: Friends or foes in cancer immunotherapy?. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-1130 (2022).","journal-title":"Clin. Cancer Res."},{"key":"60910_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1158\/1940-6207.CAPR-10-0035","volume":"3","author":"M Chen","year":"2010","unstructured":"Chen, M. et al. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non\u2013muscle-invasive bladder cancer. Cancer Prev. Res. 3, 1235\u20131245 (2010).","journal-title":"Cancer Prev. Res."},{"key":"60910_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","volume":"60","author":"M Agundez","year":"2011","unstructured":"Agundez, M. et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus calmette-gu\u00e9rin response in patients with T1G3 high-risk bladder tumours. Eur. Urol. 60, 131\u2013140 (2011).","journal-title":"Eur. Urol."},{"key":"60910_CR32","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/s41416-024-02883-5","volume":"131","author":"J-L Lu","year":"2024","unstructured":"Lu, J.-L. et al. Temporal dynamics of immune cell patterns in bladder cancer patients receiving bacillus calmette-gu\u00e9rin therapy. Br. J. Cancer 131, 1901\u20131912 (2024).","journal-title":"Br. J. Cancer"},{"key":"60910_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.155997","volume":"270","author":"MZT Lima","year":"2025","unstructured":"Lima, M. Z. T. et al. Infiltrating natural killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer. Pathol. - Res. Pract. 270, 155997 (2025).","journal-title":"Pathol. - Res. Pract."},{"issue":"450","key":"60910_CR34","first-page":"e13","volume":"42","author":"F Yilmaz","year":"2024","unstructured":"Yilmaz, F. & Sagir, S. Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method?. Urol. Oncol. Semin. Orig. Investig. 42(450), e13-450.e22 (2024).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"60910_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-023-00460-1","volume":"11","author":"E Zhang","year":"2023","unstructured":"Zhang, E. et al. Roles and mechanisms of tumour-infiltrating B cells in human cancer: A new force in immunotherapy. Biomark. Res. 11, 28 (2023).","journal-title":"Biomark. Res."},{"key":"60910_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 15, 14 (2023).","journal-title":"Genome Med."},{"key":"60910_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008636","volume":"12","author":"R Flippot","year":"2024","unstructured":"Flippot, R. et al. B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors. J. Immunother. Cancer 12, e008636 (2024).","journal-title":"J. Immunother. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60910-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:23:37Z","timestamp":1792056217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60910-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60910"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60910-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Army Medical Center (Approval No. 202517). Given its retrospective design, informed consent was waived by the Ethics Committee of the Army Medical Center.","order":2,"name":"Ethics","label":"Ethical approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31774"}}